NovaBay Pharmaceuticals, Inc.
NBY
$1.03
$0.4371.67%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -50.72% | -33.72% | -6.77% | -20.01% | -27.75% |
| Total Other Revenue | 600.00% | -- | -- | -77.50% | -95.00% |
| Total Revenue | -50.59% | -33.47% | -6.45% | -20.21% | -27.95% |
| Cost of Revenue | -9.91% | -54.43% | -62.14% | -64.40% | -68.72% |
| Gross Profit | 12.75% | -30.98% | -49.13% | -60.39% | -63.25% |
| SG&A Expenses | 19.94% | 2.53% | -8.01% | -30.44% | -35.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.67% | -13.26% | -24.38% | -40.84% | -46.01% |
| Operating Income | -23.66% | -32.09% | -52.56% | -3.35% | -1.30% |
| Income Before Tax | 3.89% | -3.74% | -23.82% | 36.63% | 28.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.89% | -3.74% | -23.82% | 36.63% | 28.64% |
| Earnings from Discontinued Operations | 542.93% | 444.40% | 111.04% | -91.14% | -258.69% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 131.17% | 132.94% | 25.07% | 26.34% | 11.99% |
| EBIT | -23.66% | -32.09% | -52.56% | -3.35% | -1.30% |
| EBITDA | -24.25% | -32.91% | -53.62% | -5.64% | -5.63% |
| EPS Basic | 100.40% | 99.49% | 76.04% | 67.18% | 74.18% |
| Normalized Basic EPS | 97.05% | 95.58% | 55.70% | 58.50% | 42.38% |
| EPS Diluted | 100.40% | 99.49% | 76.04% | 67.18% | 74.18% |
| Normalized Diluted EPS | 97.07% | 95.59% | 55.70% | 58.50% | 42.38% |
| Average Basic Shares Outstanding | 1,321.52% | 3,251.41% | 2,603.04% | 1,436.80% | 545.02% |
| Average Diluted Shares Outstanding | 1,328.18% | 3,271.15% | 2,603.04% | 1,436.80% | 545.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |